Search
01/10/2025
Economic Burden of Disease Management and Recurrences After Complete Resection of Early-Stage ALK plus Non-Small Cell Lung Cancer (NSCLC) in Spain
Bernabé, R, De Castro, J, Collado, R, Escudero, V, Gutiérrez, F, Arranz, S, Gordo, R, Arroyo, I, Majem, M. Economic Burden of Disease Management and Recurrences After Complete Resection of Early-Stage ALK plus Non-Small Cell Lung Cancer (NSCLC) in Spain. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2025
Phase 3 eVOLVE-Lung02 Trial of Volrustomig plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic NSCLC With PD-L1 TC <50%
Johnson, ML, Arriola, E, Kato, T, Girard, N, Gadgeel, S, Tarruella, MM, Newsom-Davis, T, Polaczek, M, Chen, X, Stefaniak, K, Lowery, C, Angra, N, Doherty, G, Ahn, MJ. Phase 3 eVOLVE-Lung02 Trial of Volrustomig plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic NSCLC With PD-L1 TC <50%. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2025
Non-Pharmacological Dermatologic Care for the Prevention and Management of Immune-Related Skin Toxicities in Patients With Lung Cancer
Lopez, JS, Besora, CP, Verge, MM, Joaquin, AB, Recio, SM, Pastor, M, Fierro, JP, Martinez-Esparza, EH, Martinez-Momblan, MA, Majem, M. Non-Pharmacological Dermatologic Care for the Prevention and Management of Immune-Related Skin Toxicities in Patients With Lung Cancer. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2025
Histological Transformation as Resistance Mechanism in NSCLC: A Multicenter Study Exploring Clinico-Pathological and Molecular Features
Torresan, S, Torres, CSD, Caramella, C, Ambrosini, P, Gomez-Randulfe, I, Monaca, F, Ribera, A, Goudsmit, A, Michelini, A, Segui, V, Insa, A, Martorell, PM, Romero-Sola, G, Caro-Consuegra, R, Mirallas, O, Priano, I, Valdivia, A, Masfarré, L, Iranzo, P, Martinez-Marti, A, Cedres, S, Catot, S, Sequeira, T, Callejo, A, Bearz, A, Barba, A, Antoñanzas, M, Sais, E, Baena, J, Brandao, M, Mosteiro, M, Vilariño, N, Gambardella, V, Moran, T, Occhipinti, M, Califano, R, Pardo, N, Felip, E, Rocha, P. Histological Transformation as Resistance Mechanism in NSCLC: A Multicenter Study Exploring Clinico-Pathological and Molecular Features. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2025
Benefits of Adjuvant Alectinib in ALK plus Early-Stage Non-Small Cell Lung Cancer, Recurrences Avoided and Savings for the Spanish Health System
De Castro, J, Bernabé, R, Escudero, V, Gutiérrez, F, Majem, M, Gordo, R, Arroyo, I, Arranz, S, Collado, R. Benefits of Adjuvant Alectinib in ALK plus Early-Stage Non-Small Cell Lung Cancer, Recurrences Avoided and Savings for the Spanish Health System. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2025
IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration
Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Sanchez, AYC, Bustillos, A, Herraez-Baranda, L, Barata, T, Young, F, Majem, M. IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).